AngioDynamics, Inc. has announced a new pulmonary embolism research initiative. The company selected Jacobi Hospital in Bronx, New York, for an ALPHA-PE Research Fund award. Dr. Jonathan Alis, Dr. Seth I. Sokol, and their team will lead the independent study. The research receives support through a partnership with The PERT Consortium®.
The study will examine CT pulmonary angiography radiomics in patients with pulmonary embolism (PE). Researchers will assess imaging features linked to thrombus biology and thrombectomy success. The team will also examine longer-term outcomes among patients receiving treatment for PE. Therefore, the study could add valuable real-world evidence to pulmonary embolism research.
PE continues to present a major clinical challenge for healthcare providers. Physicians need stronger real-world evidence to guide treatment decisions. Mechanical thrombectomy remains an established option for large vessel occlusions. However, complete recanalization does not occur in every case. Earlier research has indicated that imaging characteristics may reveal information about clot composition. Yet, physicians currently have limited tools for evaluating thrombus biology through CT pulmonary angiography.
They also have limited information for predicting how a clot may respond to mechanical thrombectomy. As a result, additional research could help address important gaps in PE treatment.
“The selection of this proposal from Dr. Alis, Dr. Sokol and the team at Jacobi Hospital reflects the purpose of the ALPHA-PE Research Fund: supporting rigorous, physician-led research that can help close evidence gaps in pulmonary embolism care,” said Laura Piccinini, AngioDynamics Senior Vice President and General Manager, Cardiovascular & International. “This program reinforces AngioDynamics’ commitment to partnering with the clinical community, investing in evidence generation and supporting research that may help physicians improve care for patients with PE.”
Study to Examine Thrombus Biology and Treatment Outcomes
The Jacobi Hospital study will assess imaging biomarkers associated with thrombus composition. Researchers will also examine whether these biomarkers can predict thrombectomy success. The study will further evaluate the patient’s longer-term disease trajectory. In addition, the research aims to generate clinically relevant evidence for PE care.
The findings could help physicians identify patients who may benefit from intervention. They could also support more individualized treatment planning. Furthermore, the research may strengthen the growing evidence base surrounding pulmonary embolism treatment. It may also improve understanding of how imaging can support clinical decisions.
AngioDynamics launched the ALPHA-PE Research Fund with The PERT Consortium®. The program supports independent research led by physicians in the PE care field. The initiative focuses on critical evidence gaps affecting pulmonary embolism treatment. It also supports research into patient outcomes and healthcare workflows.
ALPHA-PE Research Fund Supports Independent Studies
The competitive program offers awards ranging from $50,000 to $750,000. Funding can support studies lasting between one and three years. Eligible research areas include patient outcomes and workflow optimization. The program also supports novel therapeutic approaches with potential clinical value. The initiative aims to advance research that could improve real-world PE care. Therefore, independent studies remain an important part of the program’s goals.
“The PERT Consortium® is pleased to support this proposal from Dr. Alis, Dr. Sokol and their team at Jacobi Hospital through the ALPHA-PE Research Fund,” said Amir Darki, MD, Co-Chair of the National PERT Research Consortium. “Independent, investigator-driven research is essential to advancing the evidence base in pulmonary embolism. This study addresses an important clinical question and has the potential to provide insights that are meaningful to physicians, patients and the broader PE community.”
The Jacobi Hospital team will focus on the information contained within CT pulmonary angiography images. The research will assess whether radiomic features can provide additional clinical insights.
“CT pulmonary angiography is already central to the diagnosis and assessment of pulmonary embolism, but there is potentially much more information within those images than we are using today,” said Dr. Sokol. “Our goal is to determine whether radiomic features can help us better understand the biology of a patient’s clot and predict how it will respond to mechanical thrombectomy. If validated, this research could ultimately give physicians another tool to inform treatment decisions and support a more individualized approach to PE care.”
The PERT Consortium® Advances PE Care
The PERT Consortium® works to advance the standard of pulmonary embolism care. It also promotes research focused on PE treatment and patient management. The Consortium supports adoption of the PERT model across healthcare settings. In addition, it promotes scientific research related to pulmonary embolism. The organization also provides education for healthcare professionals and the public. Its educational efforts cover pulmonary embolism diagnosis, treatment, and ongoing care.
Through the ALPHA-PE Research Fund, AngioDynamics and The PERT Consortium® continue supporting physician-led research. The Jacobi Hospital study adds another effort focused on improving evidence around PE care. The research may provide new insights into thrombus biology and treatment response. It could also contribute to more informed and individualized pulmonary embolism treatment decisions.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
